Lori Macomber's most recent trade in Karyopharm Therapeutics Inc was a trade of 1,626 Common Stock done at an average price of $6.3 . Disclosure was reported to the exchange on Feb. 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc | Lori Macomber | EVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 6.30 per share. | 03 Feb 2026 | 1,626 | 85,105 (0%) | 0% | 6.3 | 10,244 | Common Stock |
| Karyopharm Therapeutics Inc | Lori Macomber | EVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2026 | 32,415 | 86,731 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Lori Macomber | EVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2025 | 43,650 | 54,316 (0%) | 0% | 0 | Common Stock | |
| Karyopharm Therapeutics Inc | Lori Macomber | EVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 650,000 | 650,000 | - | - | Stock Option (right to buy) | |
| Karyopharm Therapeutics Inc | Lori Macomber | EVP, CFO & Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 160,000 | 160,000 (0%) | 0% | 0 | Common Stock |